Health Catalyst, Inc. (HCAT) vs Atrium Therapeutics, Inc. (RNA)
A side-by-side comparison of Health Catalyst, Inc. and Atrium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HCAT
Health Catalyst, Inc.
$1.77HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RNA
Atrium Therapeutics, Inc.
$7.99HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — HCAT vs RNA
growth of $100 · dividends reinvested · last 1yHCAT +0.6% (+0.6%/yr)RNA -46.0% (-46.0%/yr)HCAT compounded faster over this window
HCAT RNA
HCAT vs RNA: by the numbers
- •RNA is the larger company ($137M vs $131M market cap).
- •Both run net losses; HCAT's is the smaller (-90.61% vs -396.52% net margin).
Metrics side by side
Valuation
| Metric | HCAT | RNA |
|---|---|---|
| P/S ratio | 0.45 | 5.82 |
| P/B ratio | 1.30 | 0.64 |
| EV / EBITDA | 74.38 | N/A |
| FCF yield | 9.99% | N/A |
Profitability
| Metric | HCAT | RNA |
|---|---|---|
| Gross margin | 33.47% | 97.90% |
| Operating margin | -11.60% | -410.23% |
| Net margin | -90.61% | -396.52% |
| ROE | -262.64% | -43.42% |
| ROIC | -21.42% | -38.45% |
Growth (annualized)
| Metric | HCAT | RNA |
|---|---|---|
| Revenue CAGR (5Y) | 6.24% | N/A |
| Total return CAGR (5Y) | -48.35% | N/A |
Go deeper
Dig into the metrics
Health Catalyst ROEAtrium Therapeutics ROEHealth Catalyst operating marginAtrium Therapeutics operating marginHealth Catalyst revenue growthAtrium Therapeutics revenue growthHealth Catalyst free cash flowAtrium Therapeutics free cash flow
Health Catalyst & Atrium Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.